NIP
OKUR

Nicholas Investment Partners’s OnKure Therapeutics OKUR Stock Holding History

Nicholas Investment Partners’s Portfolio OKUR Stock Details OKUR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-22,619
Closed -$2.11M – 213
2021
Q2 		$2.11M Buy
+22,619
New +$2.52M 0.13% 155

Other funds holding OKUR

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
RVM
RiverVest Venture Management St. Louis, Missouri $6.84M AUM 7.71% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
TCM
Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Nicholas Investment Partners's OKUR Position: Q3 2021 in Review

Nicholas Investment Partners sold out of OnKure Therapeutics (OKUR) in Q3 2021, closing a stake of 22,619 shares — an estimated $2.11M sold.

Nicholas Investment Partners first reported a position in OKUR in Q2 2021 and held it in 1 quarter. The position peaked at $2.11M in Q2 2021. 38 funds tracked by Wall St. Rank hold OKUR as of Q3 2021.

  • Nicholas Investment Partners reported no remaining OnKure Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Nicholas Investment Partners sold 22,619 OnKure Therapeutics shares in Q3 2021, an estimated $2.11M.
  • Nicholas Investment Partners first reported a position in OnKure Therapeutics in Q2 2021 and held it in 1 quarter.
  • Nicholas Investment Partners's OnKure Therapeutics position peaked at $2.11M in Q2 2021.
  • 38 funds tracked by Wall St. Rank held OnKure Therapeutics as of Q3 2021.

Based on Nicholas Investment Partners's 13F filing for Q3 2021, filed 15 Nov 2021.